商品编号


AG-CR1-3667-M005



品牌


Adipogen



公司


Adipogen



公司分类


Cancer



Size

5 mg


商品信息


More Information



Product Details



Synonyms

Cpd 51; S-(7-Oxo-7-((4-phenylthiazol-2-yl)amino)heptyl) 2-methylpropanethioate



Product Type

Chemical



Properties



Formula

C
20
H
26
N
2
O
2
S
2




MW

390.56



CAS

848354-66-5



Purity Chemicals

≥97% (HPLC)



Appearance

White crystals.



Solubility

Soluble in DMSO (25mg/ml) or ethanol (10mg/ml). Insoluble in water.



Identity

Determined by
1
H-NMR.



InChi Key

MDYDGUOQFUQOGE-UHFFFAOYSA-N



Shipping and Handling



Shipping

AMBIENT



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

Keep cool and dry.
Protect from light and moisture.



Use/St
ABI
lity

Stable for at least 2 years after receipt when stored at -20°C.



Documents



MSD
S


Download PDF



Product Specification Sheet



Datasheet


Download PDF






Potent non-hydroxamate HDAC inhibitor (HDACi) (IC
50
: 32, 48 and 41nM for HDAC4, HDAC1 and HDAC6, respectively).

Cell permeable prodrug that is intracellularly converted to the potent HDAC inhibitor NCH 31.

Predicted to exhibit a similar HDAC binding mode as that of SAHA, interacting with the active-site zinc targeting group.

Shown to exhibit comparable antiproliferative and apoptotic activity as SAHA against various cancer cell lines. Inhibits growth of various cancer cells
in vitro
(EC
50
=1.1 - 9.1μM).

Reactivates latent HIV-1 gene expression.

Active against selected neurodevelopmental disorders.



Product References

Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates: T. Suzuki, et al.; J. Med. Chem.
48,
1019 (2005)

Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells: T. Sanda, et al.; Leukemia
21,
2344 (2007)

Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor: T. Suzuki, et al.; Bioorg. Med. Chem. Lett.
17,
1558 (2007)

Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression: A.F. Victoriano, et al.; FEBS Lett.
585,
1103 (2011)

Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients? M. Martinez-Bonet, et al.; J. Virus Erad.
1,
148 (2015)

Altered neuronal network and rescue in a human MECP2 duplication model: S. Nageshappa, et al.; Mol. Psychiatry
21,
178 (2016)